Objective-To evaluate the impact of the prevalent round ofthe NHS breast screening programme on the whole population of wornen aged 50-64 during the period 1988-92, by compazing the numbers of cancers detected at screening with those diagnosed symptomatically, in one United Kingdom health region (population 3.5 million). To relate this impact to the achievement of national quality standards and the observed sensitivity and specificity of the programme. Method-The breast screening progzamrne ccmputer systems and the Thames Cancer Registry database were used to diagnose cancers in women aged 50-64 during the period 1988-1992, who were classified into screen detected, interval cases, eligible but not yet invited, nonattenders, and those not registered with the programme, Results-The progranune met all national quality assurance targets for uptake, diagnostic process, and detection, but screen detected cases ccmpzlsed only 48% of those diagnosed during 1991 and 1992 when the breast screening progranune was fully operational. As fewer than 40% of breast cancers registered occur in the eligible age range, this Iirrrits the impact of the progranune to the possible early diagnosis of only 20% of all cases. A surprisingly high proportion occurred in women unknown to the programme, especially in inner London. The high number of interval cancers led to a programme sensitivity of only 73%, but 99.7% of'women screening negative were correctly reassured as a result of screening-and for them the breast screening progranune is a success. Conclusion-Despite achievement of quality standards, the breast screening progranune is apparently having a low impact on the overall diagnosis of breast cancer in South East Thames, so a large mor-tality reduction due to screening alone is unlikely. Population coverage will need to be Improved, and it may be necessary to reduce the screening interval, or extend the age range, or both.
The United Kingdom government announced the establishment of the national breast screening programm,e in 1987. Three yearly mammographic screening was to be offered to all women aged 50-64 starting in 1988. The service was to be organised on a regional basis according to the Forrest model, 1 with the target of inviting every eligible woman by the end of 1993. Within the South East Thames region, which extends from a quadrant of inner London to the coastal towns of Kent and East Sussex, the implementation was phased over the period 1988-90. The prevalent or initial screening round was therefore not completed until the end of 1993 at the later screening units.
The aim of the programme is to reduce mortality from breast cancer, but these results will not be available for several years. Breast cancer death rates in England and Wales seem to be falling." The rates stopped increasing in the late 1980s, and by 1993 had fallen by 10% of the 1985-89 levels for women under 80. This decline was across all age ranges, but greatest for those under 50, so cannot be attributed to the NHS breast screening programme. Earlier diagnosis and better treatment are believed to be responsible, including the widespread use of tarnoxifen.' Whatever the cause, the lack of a steady baseline of mortality rates complicates this measure of programme efficacy.
There have been various attempts to evaluate the impact of the NHS breast screening programme and other such programmes in the short term, including survival analysis," increased incidence of diagnosis," tumour size and prognosis,' and the numbers of interval cancers." This project is an attempt to evaluate the prevalent round in South East Thames in terms of its impact on the whole population of women aged 50-64 by comparing the cancers detected at screening with those diagnosed symptomatically.
The NHS breast screening programme has an integral quality assurance programme, based on standards set out in the Pritchard report" and its succeeding documents. These standards, which have been surpassed by the majority of screening units, relate to the screening and diagnostic processes and treatment of screen detected cancers, but are mainly process measures. They do not measure the success of the programme from a population perspective.
Methods
The South East Thames programme consists of eight screening units organised round three main assessment centres/screening offices in Camberwell, Canterbury, and Brighton, serving the populations of South East London, Kent, and East Sussex respectively. The data required for this evaluation were located in three separate computer systems: 1 The Oxford breast screening systems in the screening offices. These systems were recently equipped with report generators, and so were able to produce feedback reports by district health authority for the period covering the prevalent round in each case.
The VAX system at the Thames Cancer
Registry. The Thames Cancer Registry aims to register all cases of cancer diagnosed in southeast England. Data on all women aged 50-64 at diagnosis within South East Thames during the period 1988-1992 were down loaded to the Microsoft Excel spreadsheet on their network. In addition to patient demographics and postcodes, tumour morphology and data on nodes and metastases were available, but not screening status. Tumour size details were inadequate for analytical purposes. The Thames Cancer Registry estimates that it takes two or three years to achieve reasonable completeness of data-for example, by summer 1994 breast cancers diagnosed in 1991 were 79% complete. This is due to the retrospective nature of the registration process, which requires review of patient notes. It is not therefore possible to go beyond 1992, and even these figures are likely to be underestimates. Some registrations are by death certificate only, others completely missed if the tumour was not a cause of death. 3 The quality assurance reference centre system at King's CoUege Hospital. This system records treatment and follow up details on all screen detected cases. Data exchanges were initiated between the Thames Cancer Registry and the breast screening programme quality assurance reference centre, who in turn had to access the screening office systems. Individual records were matched by name, previous surname, and address to determine the presentation status of each case. As a result of the matching exercise, the quality assurance reference centre also supplied the records of 300 interval and screen detected cases not registered at the Thames Cancer Registry. The process of record matching was laborious and time consuming and remains incomplete to the end of 1992. To further complicate the process both databases record cancers diagnosed, rather than being patient based. The cancer registry system allows a single patient ID with multiple entries for different tumours. It is not unusual for patients with breast cancer to present with bilateral disease or multiple lesions on the same side. For the purposes of this population based evaluation only the first most significant lesion was considered. Over 5000 records were identified, some of which were found to belong to women aged 65-69. The quality assurance Garvican, Littlejohns reference centre staff underestimated the enormity of the task, which has had to be largely manual and has required comparison of dates of screening and diagnosis in many cases. Uninvited women have not yet been checked for the second half of 1992. In each case presentation status was classified into one of the groups defined below: Screen detected cancer -A cancer detected and diagnosed as a result of the woman having an abnormal initial screen and attending for assessment through the NHS breast screening programme.
Interval cancer -A cancer diagnosed within the three year interval between screens in the NHS breast screening programme. It may be further categorised: 1 False negative screen: A failure of the screening programme, where an abnormality was visible on the original film but was not detected or followed up. 2 True new lesion: Independent revision of the screening film shows no apparent abnormality at that time. 3 Mammographically occult: Some tumours cannot be detected by mammography even when large enough to be palpable. The woman is screened negative but subsequently presents symptomatically, when the lesion is felt, during the following three years. Non-attender-A woman who was invited to the NHS breast screening programme on a given date, but failed to attend the screening unit. She was subsequently diagnosed after referral to a breast surgeon through her general practitioner (GP). Uninvited woman -A woman known to the NHS breast screening programme computer system, who would have been invited for screening but was diagnosed before that screening could take place. Not registeredwoman -One whose records cannot be matched and does not seem to have been recorded on the Oxford system or had the opportunity to be invited for screening, but who was diagnosed between 1988 and 1992. The most likely reason is that she was not registered with a GP at the crucial time. Such women represent a failure in that they did not even become known to the NHS breast screening programme after their diagnosis so could not be invited for screening as part of follow up. Table 1 shows the results for each screening programme together with the overall totals, and the national quality standards for the prevalent round.
Results

SCREENING QUALITY
Numbers of women invited
The uncorrected prior notification list is the list of women deemed to be eligible for screening according to the family health services authority records. This was checked by GPs who were asked to correct addresses, remove patients they knew to have died or to have moved away, and cease (permanently) or suspend (temporarily) women from screening on other medical grounds. Correction of the prior notification list resulted in a reduction of 10957 women for the prevalent round. The corrected prior notification list was returned to the breast screening office, where invitations were issued as appropriate. The number of women invited was deemed to be the invitations sent out minus those returned by the Post Office. Post Office returns totalled 8883, but 4449 of these were from the three inner South East London districts. The difference between the original prior notification list and those invited averaged 6.5% across the region but reached 16% in parts of South East London. The population in Kent and East Sussex is much more stable and the family health service authority registers were consequently more accurate. It is impossible to know how many women actually received. the invitation-some undelivered leners may have been discarded rather than returned to the Post Office, but the number cannot be quantified.
Attendance rates
Rates were very high across Kent but well below target in the inner South East London districts. The overall anendance rate of 71.7% exceeded the Forrest target. I
WOmen referred for assessment
Some 15 500 women were referred for assessment at weekly clinics held at six hospitals. The recall rate was 7% for the region as a whole, with all centres below the standard set at 10% of women screened. Sixty eight women failed to anend for assessment despite repeated efforts of the screening offices. We would expect about six cancers in these women and if presented symptomatically and diagnosed in the next three years these would then appear as interval cancers on the statistics.
Cancers diagnosed
In total 1426 cancers were detected, at a rate of 67 per 10000 women screened, well in excess of the target. Invasive cancers up to 10 mm in diameter are deemed to have the best prognosis and the aim of the screening programme is to facilitate their detection. Table 2 shows that the region just failed to meet this quality standard (as originally set at 15 per 10 000 women screened) in the prevalent round. However, almost 200 cancers were of unknown type or size-so that the shortfall may be due to a lack of measurement rather than radiological detection. Also the proportion of non-invasive cancers detected was considerably greater than expected. The standards were modified in 1991 to require more than 10% of cancers detected be ductal carcinoma in situ, and more increase in the total registrations over the period. This is believed to be due to the screening programme detecting some cancers earlier rather than to a true increase in incidence." By 1991 the programme was fully in operation across the region. It can be seen that only about 60% of the cancers are likely to be screen detected. The shortfall is made up of uninvited women, interval cancers arising between screens, and cancers in non-anenders. To extend the analysis it is necessary to look at individual records and assess the presentation status in each case. Tables 3 and 4 show the results. A total of 1003 records remain to be reconciled, though at least 750 of those whose presentation status cannot be confirmed, but were diagnosed in the earlier years, are likely to be uninvited, as they lived in areas which the breast screening programme had not reached at the time of diagnosis. Unlike other values, that for the screen detected cancers is the final figure.
The large number of uninvited women is to be expected in the early years of the programme, and should reduce in subsequent rounds. However, the unexpectedly large number of 525 cancers in women who were not registered on the Oxford system is a particular cause for concern, and might have a significant effect on the impact of the programme. Most of these women live in London. We identified 224 interval cancers in South East Thames up to 1992 diagnosed in women aged 50-64. This does not represent the total number of interval cancers arising from the prevalent round, however, which must include all those up to three years after the prevalent screen, and will inevitably include women up to at least 67 years of age. To date the quality assurance reference centre have identified 520 such cases, and this number will increase as the second screening round is still incomplete in two areas. The numbers of cancers arising in non-anenders was quite low up to 1992, but as with the interval cancers should be followed up until the next invitations are due. These data are not yet available.
The pie chart ( fig 2 ) shows the proportions of women presenting in these different ways during 1991 and 1992, when the programme was fully operational across the region. The majority of cancers were still not screen detected, in the 50-64 age group. Clearly, the true proportion detected by screening was less than 50%. As the incidence of breast cancer continues to increase with age after the menopause, the majority of women diagnosed are over 65 and not therefore routinely invited. Table 5 shows that fewer than 40% of the cancers registered were within the screening age range. If we can assume that the Thames Cancer Registry underregistration is consistent across the age ranges, then the NHS breast screening programme was only able to influence the early diagnosis of some 20% of all cases. Reduction in mortality is likely to be even smaller unless the programme is accompanied by improvements in diagnosis and treatment for all ages." than 20% up to 10 mm in size, and these were achieved in South East Thames.
Thus it is clear that the prevalent round of breast screening in South East Thames was successful in comparison with the national standards expected of the programme. It also ran to time, with all prevalent rounds being completed within about three years, and within budget. The total cost was of the order of £6.5 million revenue (at current pay and price levels) plus initial capital allocations of £150000 per screening unit." This works out at almost £5000 per early diagnosis. Figure 1 shows the simplest type of comparison. It can be seen that there was a progressive Data produced from the Thames Cancer Registry and National Health Service breast screening programme databases by matching of individual records using surname, forename, address, and date of birth. Uninvited women matched until end June 1992 only. Screen detected 47.9% Table 6 Results of a screening test, as applied to the prevalent round of breast screening, in South East Thames does not necessarily follow, however, that the programme is effective and efficient. This evaluation has shown that the sensitivity and specificity give some cause for concern. Ideally both should be closer to 100%. In practice there is a trade off between these two values relating to the designated cut off point for a positive test result. The combination of poor programme and good test sensitivities is a strong indication of the need to reduce the screening interval, as has been suggested elsewhere. 0 12 The recall rate of 7%, well within the national standard, translates into a positive predictive value for the initial screen of only 9.2%, so that 14000 women had a positive screen result before eventual reassurance at the assessment clinic. The recent initiative to take two views at the prevalent screen should both reduce the recall rate and help to improve the sensitivity of the test, without reducing the specificity, but it will not be possible to evaluate this nationally for some time." It will have little effect on the large numbers of interval cancers arising in the third year, if they are mainly true new lesions." Similarly, double reading, which was rarely possible in South East Thames, may improve the initial sensitivity but cannot prevent these new lesions.
POPULATION IMPACT
l1!ar of diagnosis
The New York health insurance plan breast screening project recorded a similar sensitivity (75%, counting all interval cancers diagnosed within a year as false negatives), positive predictive value, and negative predictive value but a rather better specificity of 98.5%. 15 Similarly, achievement of quality targets for uptake and acceptance of the invitation does not guarantee a high population impact. We have shown that in 1991 and 1992 the majority of cancers arising in the eligible age group presented symptomatically. The cases still to be checked should be mostly uninvited women, and are definitely not screen detected. Over subsequent screening rounds the proportion of cases arising in uninvited women should decrease to those mainly aged 50-52, but we can expect a rise in cases in the interval and non-attender groups as they are followed up through the three years until the next invitation. The two "uncooperative" groups-that is, the non-attenders and those not registered with family health service authorities, make up a significant proportion, which may not easily be reduced by health promotion activities.
The shortfall in South East London is an indicator of the particular difficulties of administering the programme in the inner city, and has been thought to be due at least in part to the inaccuracy of the family health service authority registers. I. However we believe that these results may have some relevance to the national programme, which detected 5972 cases in 1992-93 and 6030 in 1993-94 in women aged 50-64. 17 ' 0 Compared with a national incidence usually reported as 26 000" and known to be rising," this gives a similar percentage of only 23% of all cases being screen detected. Impact of the programme could be improved if the screening age range was extended up to 69 years where incidence is 
Discussion
The South East Thames breast screening programme met the national quality standards during the course of the prevalent round. It greater and mammograms become easier to interpret."
The political decision to launch the NHS breast screening programme was taken when early evidence from trials looked encouraging' but before there had been much opportunity to draw up the balance sheet of costs and risks. In 1968 Wilson and Jungner drew up a checklist of 10 criteria which should be clarified before a programme is implemented." One of these criteria is that the costs of a screening programme should be considered in the light of competing demands for health care resources. This has never really happened with the NHS breast screening programme because new money was ear-marked from the beginning. Since 1989 resource allocation has become tighter and the rationing debate intensified. Early in 1994 the chief medical officer clearly indicated that any new screening initiative would be subjected to detailed evaluation before implementation on a national scale. 22 Wright and Mueller" have been long term critics of publicly funded breast screening programmes. In a recent analysis of population benefit they conclude that the benefit of breast screening is marginal, the harm caused substantial, and the costs enormous, so that the programme is not justifiable in any age group. They calculated that the mean annual cost per life saved is around £1/2 million. However, they place no value on the benefit of reassurance to the true negatives. They concentrate on the harm caused to the false positives and imply that large numbers of these eventually come to open biopsy, which has not been found to be the case in South East Thames. Costs were calculated at around £35 000 per cancer detected. Even including indirect costs incurred by the women, this figure is much higher than our own experience, and that of other UK services."
This evaluation is therefore both relevant and timely. It is impossible to put a monetary value on the reassurance the true negatives receive from screening, but they consider it well worth submitting to the risks of the process. For almost 200 000 women in the prevalent round in South East Thames the programme is a success. Even those who believe that the programme is expensive at about £5000 per cancer diagnosed may consider it a. bargain at £33 per woman correctly reassured.
